ArticleComputational and structural biotechnology journal2026
LncRCD: A Comprehensive Database for Pan-Cancer Characterization of lncRNAs Related to 12 Regulated Cell Death Types.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulated cell death (RCD) is a fundamental biological process that determines tumor progression and treatment response. Although high-throughput sequencing technologies have revealed a large number of tumor-related long noncoding RNAs (lncRNAs), systematically analyzing the regulatory landscape of lncRNAs under multiple RCD patterns remains a challenge. Here, we present LncRCD (https://lncrcddb.bio-database.com/), a comprehensive resource and analysis platform specifically for cancer cell death-related lncRNAs. This study systematically integrated 1,595 core genes involved in 12 types of RCD and identified 4,624 pairs of RCD-lncRNA regulatory relationships in 18 cancer types, covering 2,088 lncRNAs with potential functional significance. To demonstrate the clinical translational value of this large-scale dataset, we conducted a comprehensive downstream bioinformatics analysis, including constructing a robust prognostic evaluation model based on RCD-lncRNA signatures, using the non-negative matrix factorization (NMF) algorithm to identify molecular subtypes with unique immune characteristics and survival outcomes, and predicting potential treatment drug sensitivity based on cancer treatment response portal data, thereby linking molecular phenotypes to clinical therapeutic guidance. The LncRCD database is a comprehensive resource database and a discovery-oriented platform, integrating user-friendly search, analysis, browsing, download, and visualization functions. Its aim is to provide a convenient resource for exploring the complex regulatory relationships between RCD and lncRNAs in human cancers. Ultimately, this study not only presents a panoramic view of lncRNAs participating in the regulation of multiple RCD patterns but also provides a valuable resource for linking omics data to biological interpretation, which may help elucidate tumor death mechanisms and offer insights for future precision immuno-oncology strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.